Drugmakers Target B-Cell Treatments | Chemical & Engineering News
Volume 93 Issue 1 | p. 12 | Concentrates
Issue Date: January 5, 2015

Drugmakers Target B-Cell Treatments

Department: Business
Keywords: hematology, B-cell malignancies, pharmaceuticals

Johnson & Johnson and Gilead Sciences are investing in therapies that treat B-cell malignancies. J&J will invest $75 million in MacroGenics and pay the biotech firm a $50 million fee to license MGD011, a monoclonal antibody in preclinical development as a treatment for B-cell blood cancers. The antibody is designed to redirect cancer-fighting T cells to eliminate CD19-expressing cells found in many such cancers. Separately, Gilead will license Ono Pharmaceutical’s ONO-4059, a small-molecule Bruton’s tyrosine kinase inhibitor for the treatment of B-cell malignancies including chronic lymphocytic leukemia. Gilead isn’t disclosing its payments to the Japanese firm.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment